ACIP Recommendations: Diphtheria, Tetanus and Pertussis (DTaP/Tdap/Td) Vaccines

Published in Morbidity and Mortality Weekly Report (MMWR)

The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).

CURRENT DTaP/Tdap/Td Vaccine Recommendations

• MMWR, January 24, 2020, Vol 69(3);77-83
  Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019
  • Print version

• MMWR, April 27, 2018, Vol 67, (RR-2);1-44
  Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
  • Print version

See also:

• ACIP VFC Resolution

ARCHIVED Historical DTaP/Tdap/Td Vaccine Recommendations

For your convenience, these archived publications can be used for historical and research purposes.

• MMWR, September 4, 2015, Vol 64(34);948-949
  Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine and Guidance for Use as a Booster Dose
  • Print version

• MMWR, September 23, 2011, Vol 60(37);1279-1280
  FDA Approval of Expanded Age Indication for a Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine
  • Print version

• MMWR, January 14, 2011, Vol 60(01);13-15
  Updated Tdap Vaccine Recommendations from the ACIP, 2010
  • Print version

• MMWR, April 17, 2009, Vol 58(14);374-375FDA Approval of Expanded Age Indication for a Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine
  • Print version

• MMWR, August 1, 2008, Vol 57(RR-06);1-19
  Recommendations for Postexposure Interventions to Prevent Infection with Hepatitis B Virus, Hepatitis C Virus, or Human Immunodeficiency Virus, and Tetanus in Persons Wounded During Bombings and Other Mass-Casualty Events — United States, 2008
  • Print version

• MMWR, December 9, 2005, Vol 54(RR-14);1-16
  Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis: 2005 CDC Guidelines
  • Print version

• MMWR, September 26, 2003, Vol 52(38);921-921
  Notice to Readers: FDA Approval of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, (INFANRIX®) for Fifth Consecutive DTaP Vaccine Dose
  • Print version

• MMWR, November 17, 2000, Vol 49(RR-13);1-8
  Use of DTaP (Diphtheria Toxoid-Tetanus Toxoid-Acellular Pertussis) Vaccine as a Five-Dose Series
  • Print version

• MMWR, August 8, 1991, Vol 40(RR-10);1-28
  Diphtheria, Tetanus, and Pertussis: Recommendations for Vaccine Use and Other Preventive Measures (PDF not available)

Adolescents

• MMWR, March 24, 2006, Vol 55(RR-03);1-34
  Preventing Tetanus, Diphtheria, and Pertussis Among ADOLESCENTS: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccines
  • Appendix A | Appx B | Appx C | Appx D | Appx E | Appx F
    Note: If you are using the HTML version of this document, be sure to access all links to get the complete content of the document, which includes 6 important appendices.
  • Print version (includes appendices)

Adults (under 65 years old)

• MMWR, December 15, 2006, Vol 55(RR-17);1-33
  Preventing Tetanus, Diphtheria, and Pertussis Among ADULTS: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccines
  • Appendix A | Appendix B | Appendix C
    Note: If you are using the HTML version of this document, be sure to access all links to get the complete content of the document, which includes important appendices.
  • Print version

Adults 65 years and older

• MMWR, June 29, 2012, Vol 61(25);468-470
  Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Adults Aged 65 Years and Older, ACIP 2012
  • Print version

Infants and Young Children

• MMWR, March 14, 2003, Vol 52(10);203-204
  Notice to Readers: FDA Licensure of Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant), and Poliovirus Vaccine Combined, (PEDIARIX™) for Use in Infants
  • Print version
• MMWR, July 5, 2002, Vol 51(26);574
  Notice to Readers: Food and Drug Administration Approval of a Fifth Acellular Pertussis Vaccine for Use Among Infants and Young Children — United States, 2002
  • Print version
• MMWR, March 28, 1997, Vol 46(RR-7);1-25
  Pertussis Vaccination: Use of Acellular Pertussis Vaccines Among Infants and Young Children
  • Print version

Pregnancy Immunization

• MMWR, February 22, 2013, Vol 62(07);131-135
  Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women – ACIP, 2012
  • Print version
• MMWR, October 21, 2011, Vol 60(41);1424-1426
  Updated Recommendations for Use of Tdap in Pregnant Women and Persons Who Have or Anticipate Having Close Contact with an Infant Aged <12 Months – ACIP, 2011
  • Print version
• MMWR, May 30, 2008, Vol 57 (04);1-47,51
  Prevention of Pertussis, Tetanus, and Diphtheria Among Pregnant and Postpartum Women and Their Infants
  • Appendix A | Appendix B
  • Print version (includes appendices)